Stock exchange intimation

Stock Exchange Intimation

Filter:

07 May 2026 – Intimation regarding Q4FY26 earnings call
07 May 2026 – Intimation for Board Meeting
04 May 2026 – OneSource Supports Second Generic Semaglutide Approval in Canada- Enables commercialisation for the first two entrants in the world’s second-largest semaglutide market
29 Apr 2026 – OneSource’s Partner Dr. Reddy’s Laboratories receives Health Canada Approval for Generic Semaglutide Injection
28 Apr 2026 – Intimation regarding receipt of EU GMP Certificate for Sterile Product Division
21 Apr 2026 – Orbicular’s Partner secures tentative U.S. ANDA approval for a generic version of Ozempic® (Semaglutide Injection), supported by OneSource as CDMO partner
17 Apr 2026 – Intimation of the renewal of EU GMP Certification for OneSource: Flagship Unit II Facility located in Bengaluru
16 Apr 2026 – Intimation of ESG Rating received from NSE Sustainability Ratings and Analytics Limited
9 Apr 2026 – Allotment of 21,450 equity shares under ONESOURCE ESOP Scheme 2021
25 Mar 2026 – Intimation regarding closure of Trading Window
20 Mar 2026 – Disclosure under Regulation 46 of the SEBI (LODR) Regulations, 2015
Schedule of Analyst / Institutional Investor’s Meet – March 09, 2026
Schedule of Analyst / Institutional Investor’s Meet – November 18, 2025 to November 20, 2025
Schedule of Analyst / Institutional Investor’s Meet – November 18, 2025 to November 20, 2025
Schedule of Analyst / Institutional Investor’s Meet – September 25, 2025 and September 29, 2025